Drug Profile
ANX 005
Alternative Names: ANX-005Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Annexon
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Complement C1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Guillain-Barre syndrome
- Phase II Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Huntington's disease
- No development reported Autoimmune disorders; Neurodegenerative disorders
Most Recent Events
- 12 Apr 2024 Annexon Biosciences plans to submit BLA for Guillain-Barre syndrome in 2H of 2024 (Annexon Biosciences pipeline, April 2024)
- 12 Apr 2024 Annexon Biosciences plans a phase II/III trial in Amyotrophic lateral sclerosis (IV) (Annexon Biosciences pipeline, April 2024)
- 27 Mar 2024 Annexon completes a phase IIa trial in Amyotrophic lateral sclerosis in USA, Canada and France (IV)